Well, it appears the comments of many BIT followers are...

Well, it appears the comments of many BIT followers are vindicated in the latest response by Biotron managemnet to a query from the ASX:

"The clinical trial is designed to test both the safety and efficacy of the Company's anti-HCV
drug ('BIT225'). As a blinded study, efficacy results will not be known until completion of the
trial, however, an important inference which can be made from the fact that the trial has not
been suspended is that the safety objectives of the trial are currently being achieved."

Patience brothers and sisters....